Clinical Trials
49 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05355701 2026-05-14
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
Phase 1 Recruiting
NCT05867121 2026-04-27
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT06385925 2026-04-24
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT06131840 2026-04-20
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT06586515 2026-04-20
MOONRAY-01
Eli Lilly and Company
Phase 1 Recruiting
NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT05891171 2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT04043195 2025-05-28
NSCLC
University of California, San Diego
Phase 1/2 Active not recruiting
NCT06963502 2025-05-09
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02889666 2024-04-17
CCODG-NSCLC
Shanghai Jiao Tong University School of Medicine
Phase 1 Recruiting
NCT00343408 2023-08-04
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
Canadian Cancer Trials Group
Phase 1 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00859469 2019-10-30
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
Phase 2 Completed
NCT00268151 2018-03-05
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
University of Louisville
Phase 1 Terminated
NCT00356941 2017-11-29
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00612677 2017-03-23
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03034850 2017-01-27
Thrombin Generation and Platelet Activation in CRS/HIPEC
Ziekenhuis Oost-Limburg
Completed
NCT00305786 2016-12-15
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Miami
Phase 2 Completed
NCT01243775 2015-08-17
BELOXAN
Chonnam National University Hospital
Phase 2 Completed
NCT00240097 2014-11-27
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
University of Alabama at Birmingham
Phase 2 Completed
NCT00145418 2014-06-30
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
Oncology Specialists, S.C.
Phase 2 Terminated
NCT00406302 2014-04-29
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Medical University of Vienna
Phase 2 Completed
NCT00004126 2013-02-11
Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer
University of Chicago
Phase 2 Completed
NCT00251524 2012-05-11
A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC
Veeda Oncology
Phase 2 Completed
NCT01497041 2011-12-22
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Korean South West Oncology Group
Phase 2 Unknown
NCT01222312 2011-11-29
Taxelox
Krankenhaus Nordwest
Phase 2 Completed
NCT00996385 2011-10-31
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Columbia University
Phase 2 Unknown
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00452881 2010-10-25
Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC
National Cancer Center, Korea
Phase 2 Unknown
NCT00453115 2010-10-25
Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
National Cancer Center, Korea
Phase 2 Unknown
NCT00271271 2009-12-07
GON
Sanofi
Phase 2 Completed
NCT00923637 2009-06-18
Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT00087802 2009-04-16
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 3 Completed
NCT00217282 2008-05-22
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00316433 2007-04-05
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
Swedish Medical Center
Phase 2 Terminated
NCT00238849 2005-10-14
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Integrated Community Oncology Network
Phase 2 Unknown